lifestyle.newsblaze.com

Author: Acrivon Therapeutics, Inc

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

April 17, 2026
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 15, 2026
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

March 19, 2026
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

March 17, 2026
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

February 23, 2026
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

February 18, 2026
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

January 24, 2026